MedTrace Logo

Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases

NCT00080912 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2023-08-21

Study results available
· View outcomes & findings →

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether single-fraction (single-dose) re-irradiation therapy is as effective as multiple-fraction (many small doses of radiation therapy) re-irradiation therapy in relieving bone pain caused by bone metastases.

PURPOSE: This randomized phase III trial is studying single-dose radiation therapy to see if it works as well as multiple-dose radiation therapy in treating patients previously irradiated with painful bone metastases.

Conditions

Interventions

RADIATION

radiation therapy

Given in a single fraction or multiple fractions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • Trans Tasman Radiation Oncology Group

    collaborator OTHER

  • Cancer Research UK

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Edward LW Chow, MD · Toronto Sunnybrook Regional Cancer Centre

  • William F. Hartsell, MD · Advocate Good Samaratin Cancer Centre

  • Daniel Roos, MD · Royal Adelaide Hospital Cancer Centre

  • Yvette von der Linden · Radiotherapeutic Institution Friesland

  • Peter Hoskin · Mount Vernon Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-22
Primary Completion
2013-04-10
Completion
2014-01-16

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00080912 on ClinicalTrials.gov